ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas-Reference-Cited by-同舟云学术

ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas

Published:2022-11-09 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Chaluts Danielle,Dullea Jonathan T.^ORCID,Ali Muhammad,Vasan Vikram,Devarajan Alex,Rutland John W.,Gill Corey M.,Ellis Ethan,Kinoshita Yayoi,McBride Russell B.,Bederson Joshua,Donovan Michael,Sebra Robert,Umphlett Melissa,Shrivastava Raj K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04442-y.pdf

Reference31 articles.

1. Abedalthagafi MS et al (2015) ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet 208(6):345–350. https://doi.org/10.1016/j.cancergen.2015.03.005

2. Bailey MH et al (2018) Comprehensive characterization of cancer driver genes and mutations. Cell 173(2):371-385.e18. https://doi.org/10.1016/j.cell.2018.02.060

3. Bui C-B et al (2019) ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Mol Carcinog 58(11):1998–2007. https://doi.org/10.1002/mc.23091

4. Choudhury A et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54(5):649–659. https://doi.org/10.1038/s41588-022-01061-8

5. El-Habr EA et al (2014) Complex interactions between the components of the PI3K/AKT/MTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Arch 465(4):473–485. https://doi.org/10.1007/s00428-014-1641-3

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-23

2. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients;Neuro-Oncology;2024-05-02

3. Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers;Exploration of Targeted Anti-tumor Therapy;2023-08-31

4. DNA methylation meningioma biomarkers: attributes and limitations;Frontiers in Molecular Neuroscience;2023-07-10

5. NF2 mutation associated with accelerated time to recurrence for older patients with atypical meningiomas;British Journal of Neurosurgery;2023-04-25